Navigation Links
Drug combination acts against aggressive chronic lymphocytic leukemia
Date:12/10/2012

ATLANTA - A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

Researchers presented the results today at the 54th annual meeting of the American Society of Hematology (ASH).

"This is a patient population with a great need for more targeted therapies," said Jan Burger, M.D., Ph.D., associate professor in MD Anderson's Department of Leukemia. Burger was lead author of the study.

"Many CLL patients, especially those with indolent or non-aggressive disease, do well on the standard treatment of chemotherapy and antibodies," he said. "But for a certain subset of high-risk patients, treatment often fails, and remissions, if they are achieved, are short."

According to the National Cancer Institute's Surveillance Epidemiology and End Results database, CLL is the most common type of adult leukemia in the United States. An estimated 16,000 new cases will be diagnosed this year, and about 4,600 people will die because of the disease. Median age of diagnosis is 72, and it is more common in men than women.

Although chemotherapy combinations have improved the cure rate for CLL, side effects often are severe. A sizeable number of CLL deaths are from secondary cancers caused by treatment.

Early studies showed potential

Ibrutinib, a tyrosine kinase inhibitor that thwarts B-cell receptor signaling, is a promising new targeted therapy for mature B-cell malignancies, including certain types of myeloma and lymphoma. It has been shown to be especially effective in CLL.

Over the past two years, Phase 1/2 trials at MD Anderson and other sites showed high-risk CLL patients responded as well as low-risk patients to ibrutinib. However, the response often is lessened because of persistent lymphocytosis, an increase in leukemia cells in the blood due to release of CLL cells from the tissues (lymph glands) into the blood stream. Rituximab, a well-established antibody, was added to capture the CLL cells in the blood and thereby accelerate and improve response.

"When we looked at how well the high-risk patients were doing on ibrutinib - even though it was a small number - we saw a great opportunity to find out if combining the two drugs would have a positive impact on these patients," Burger said.

Combination tolerated well

Forty patients with high-risk CLL were enrolled in the study earlier this year. They received:

  • Daily oral doses of 420 mg ibrutinib throughout treatment
  • Weekly infusions of rituximab (375 mg/m2) weeks one through four
  • Monthly rituximab infusions for the next five months

At a median follow up of four months, 38 patients remained on ibrutinib therapy without disease progression. One patient died from an unrelated infectious complication, and one patient discontinued therapy due to oral ulcers.

Preliminary results: 85 percent response rate

Of 20 patients evaluated for early response at three months, 17 achieved partial remission for an overall response rate of 85%. Three achieved partial remission with persistent lymphocytosis.

Interestingly, lymphocytosis peaked earlier and the duration was shorter than with ibrutinib alone.

Treatment was well tolerated, with 13 cases of grade 3 or grade 4 toxicities, including neutropenia, fatigue, pneumonia, insomnia and bone aches. Most side effects were unrelated and transient. Many patients reported improved overall health and quality of life after three cycles of treatment.

"Although this study has a short follow-up time, we are encouraged by the fact that the vast majority of patients are responding and are able to continue on treatment, Burger said.

Development of ibrutinib for CLL crucial

Researchers said these data, together with the previous Phase 1/2 studies, emphasize the need for rapid further development of ibrutinib for high-risk CLL patients.

Pharmacyclics, the company that is developing ibrutinib, is proceeding with a Phase 3 multi-center clinical trial, in which MD Anderson will participate. Additionally, MD Anderson researchers will conduct a follow-up study on their research in high-risk CLL patients.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Scientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments
2. Combination treatment may improve survival of breast cancer patients with brain metastases
3. Drug combination against NRAS-mutant melanoma discovered
4. Combination peptide therapies might offer more effective, less toxic cancer treatment
5. DNDi and Cipla to develop 4-in-1 pediatric antiretroviral drug combination
6. BUSM in vitro study identifies potential combination therapy for breast cancer
7. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
8. Discovery suggests new combination therapy strategy for basal-like breast cancers
9. Cancer vaccine combination therapy shows survival benefit in breast cancer
10. Combination of 2 drugs reverses liver tumors
11. Immunotherapy for elderly cancer patients finds new promise in drug combination
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug combination acts against aggressive chronic lymphocytic leukemia
(Date:12/6/2016)... ... December 06, 2016 , ... “Tatiana ... a powerful woman's story of sacrifice and enlightenment. , “Tatiana Sibirskaya: ... Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward writing through the ...
(Date:12/6/2016)... Dublin, CA (PRWEB) , ... December 06, 2016 ... ... Community College District , the only authorized OSHA Training Institute Education Center headquartered ... Health Fundamentals certificate program focused on providing occupational safety and health training to ...
(Date:12/5/2016)... ... December 05, 2016 , ... What: Shriners Hospitals for Children, with the help ... patients – using a video monitor and web-enabled camera. Santa visits with children through ... into a Christmas Wonderland, which is where the video connection to the North Pole ...
(Date:12/5/2016)... Tacoma, Washington (PRWEB) , ... December 05, 2016 ... ... grand opening of its latest transitional care facility – Avamere Transitional Care ... The 39,936 square foot short-term, post-acute health care center will provide patients recovering ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... relationship-marketing firm, announced today that nominations will be accepted from December 5, ... Central Awards. , Awards include the Information Security Executive® of the Year, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec 5, 2016 Research and ... by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease Diagnostics), ... Global Forecasts to 2021" report to their offering. ... , , ... 730.7 Million in 2021 from USD 574.8 Million in 2016, growing ...
(Date:12/5/2016)... 5, 2016 According to a new market ... Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), Application (Hyaline Cartilage, ... market is projected to reach USD 779.8 Million by 2021 from ... during the forecast period of 2016 to 2021. ... ...
(Date:12/5/2016)... India , December 5, 2016 According to a ... Type and by Application - Global Opportunity Analysis and Industry Forecast, 2014 - ... is expected to reach $5,255 million by 2022, growing at a CAGR of ... with more than four-fifths share. Continue Reading ... ...
Breaking Medicine Technology: